Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
The PODO Trial for People with FSGS
Trial To Evaluate PF-06730512 In Adults With Focal Segmental Glomerulosclerosis (FSGS)
Brief Description
The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adults with FSGS. The intention is to evaluate drug safety, as well as to obtain an early indication of effectiveness (how well the drug works at improving Urine Protein to Creatinine Ratio, which is a marker of kidney damage).
Trial Physician / Study Coordinator
Ahmed Awad
EmailSite Name
Clinical Research Consultants, LLC
3930 Washington Street, Kansas City, MO 64111
Sponsor
Pfizer Inc.
Study Drug
PF-06730512
Estimated enrollment
44
Estimated end date
May, 2023
Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
The PODO Trial for People with FSGS
Trial To Evaluate PF-06730512 In Adults With Focal Segmental Glomerulosclerosis (FSGS)
Brief Description
The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adults with FSGS. The intention is to evaluate drug safety, as well as to obtain an early indication of effectiveness (how well the drug works at improving Urine Protein to Creatinine Ratio, which is a marker of kidney damage).
Trial is for people with
Focal segmental glomerulosclerosis (FSGS)
Study Goal
To evaluate the safety, tolerability, and, possibly, effectiveness of PF-06730512 in people with FSGS.
What is involved for the Patient?
Adults will participate for about 8.5 months, and will receive the study drug by intravenous infusion every 2 weeks over a 12 week period.
About the drug or intervention
PF-06730512 works as an antagonist, meaning it possibly reduces a biologic activity that is associated with FSGS. PF-06730512 has been designed to affect the podocyte, which, when working properly, is associated with normal kidney function.